BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21858809)

  • 1. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples.
    Fekete T; Rásó E; Pete I; Tegze B; Liko I; Munkácsy G; Sipos N; Rigó J; Györffy B
    Int J Cancer; 2012 Jul; 131(1):95-105. PubMed ID: 21858809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy.
    Kataoka F; Tsuda H; Arao T; Nishimura S; Tanaka H; Nomura H; Chiyoda T; Hirasawa A; Akahane T; Nishio H; Nishio K; Aoki D
    Genes Chromosomes Cancer; 2012 Mar; 51(3):300-12. PubMed ID: 22095904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.
    Zhao L; Li Y; Zhang Z; Zou J; Li J; Wei R; Guo Q; Zhu X; Chu C; Fu X; Yue J; Li X
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33135729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
    Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
    J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
    Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.
    Welsh JB; Zarrinkar PP; Sapinoso LM; Kern SG; Behling CA; Monk BJ; Lockhart DJ; Burger RA; Hampton GM
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1176-81. PubMed ID: 11158614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
    Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
    Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.
    Konstantinopoulos PA; Cannistra SA; Fountzilas H; Culhane A; Pillay K; Rueda B; Cramer D; Seiden M; Birrer M; Coukos G; Zhang L; Quackenbush J; Spentzos D
    PLoS One; 2011 Mar; 6(3):e18202. PubMed ID: 21479231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential gene expression in ovarian carcinoma: identification of potential biomarkers.
    Hibbs K; Skubitz KM; Pambuccian SE; Casey RC; Burleson KM; Oegema TR; Thiele JJ; Grindle SM; Bliss RL; Skubitz AP
    Am J Pathol; 2004 Aug; 165(2):397-414. PubMed ID: 15277215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
    PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival.
    Elgaaen BV; Olstad OK; Sandvik L; Odegaard E; Sauer T; Staff AC; Gautvik KM
    PLoS One; 2012; 7(9):e46317. PubMed ID: 23029477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
    Guo Y; Fu P; Zhu H; Reed E; Remick SC; Petros W; Mueller MD; Yu JJ
    Oncol Rep; 2012 Jan; 27(1):286-92. PubMed ID: 21971700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
    Ruan L; Xie Y; Liu F; Chen X
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():31-38. PubMed ID: 29353130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
    Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
    J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic 11 genes expression model for ovarian cancer.
    Men CD; Liu QN; Ren Q
    J Cell Biochem; 2018 Feb; 119(2):1971-1978. PubMed ID: 28817186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.